Trial Profile
First-in-human Phase I Clinical Trial of a Combined Immune Modulatory Approach Using TetMYB Vaccine and Anti-PD1 Antibody in Patients With Advanced Solid Cancer Including Colorectal or Adenoid Cystic Carcinoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Colorectal cancer vaccine (Primary) ; Tislelizumab (Primary)
- Indications Adenoid cystic carcinoma; Colorectal cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms MYPHISMO
- 13 Feb 2023 Status changed from active, no longer recruiting to completed.
- 16 May 2022 Planned primary completion date changed from 30 Dec 2019 to 30 Dec 2022.
- 16 May 2022 Status changed from not yet recruiting to active, no longer recruiting.